337 related articles for article (PubMed ID: 33665361)
1. Tumor immune microenvironment-based classifications of bladder cancer for enhancing the response rate of immunotherapy.
Meng J; Lu X; Zhou Y; Zhang M; Ge Q; Zhou J; Hao Z; Gao S; Yan F; Liang C
Mol Ther Oncolytics; 2021 Mar; 20():410-421. PubMed ID: 33665361
[TBL] [Abstract][Full Text] [Related]
2. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy.
Chen YP; Wang YQ; Lv JW; Li YQ; Chua MLK; Le QT; Lee N; Colevas AD; Seiwert T; Hayes DN; Riaz N; Vermorken JB; O'Sullivan B; He QM; Yang XJ; Tang LL; Mao YP; Sun Y; Liu N; Ma J
Ann Oncol; 2019 Jan; 30(1):68-75. PubMed ID: 30407504
[TBL] [Abstract][Full Text] [Related]
3. TIMEAS, a promising method for the stratification of testicular germ cell tumor patients with distinct immune microenvironment, clinical outcome and sensitivity to frontline therapies.
Meng J; Gao J; Li X; Gao R; Lu X; Zhou J; Yan F; Wang H; Liu Y; Hao Z; Zhang X; Liang C
Cell Oncol (Dordr); 2023 Jun; 46(3):745-759. PubMed ID: 36823338
[TBL] [Abstract][Full Text] [Related]
4. Identification and validation of tumour microenvironment-based immune molecular subgroups for gastric cancer: immunotherapeutic implications.
Zhou YJ; Zhu GQ; Lu XF; Zheng KI; Wang QW; Chen JN; Zhang QW; Yan FR; Li XB
Cancer Immunol Immunother; 2020 Jun; 69(6):1057-1069. PubMed ID: 32100076
[TBL] [Abstract][Full Text] [Related]
5. Establishment of a tumor immune microenvironment-based molecular classification system of breast cancer for immunotherapy.
Zheng X; Li L; Yu C; Yang J; Zhao Y; Su C; Yu J; Xu M
Aging (Albany NY); 2021 Nov; 13(21):24313-24338. PubMed ID: 34762599
[TBL] [Abstract][Full Text] [Related]
6. Immune response drives outcomes in prostate cancer: implications for immunotherapy.
Meng J; Zhou Y; Lu X; Bian Z; Chen Y; Zhou J; Zhang L; Hao Z; Zhang M; Liang C
Mol Oncol; 2021 May; 15(5):1358-1375. PubMed ID: 33338321
[TBL] [Abstract][Full Text] [Related]
7. Immune Signature-Based Risk Stratification and Prediction of Immunotherapy Efficacy for Bladder Urothelial Carcinoma.
Liang F; Xu Y; Chen Y; Zhong H; Wang Z; Nong T; Zhong J
Front Mol Biosci; 2021; 8():673918. PubMed ID: 35004839
[TBL] [Abstract][Full Text] [Related]
8. Unraveling tumor microenvironment heterogeneity in malignant pleural mesothelioma identifies biologically distinct immune subtypes enabling prognosis determination.
Yang K; Yang T; Yang T; Yuan Y; Li F
Front Oncol; 2022; 12():995651. PubMed ID: 36237331
[TBL] [Abstract][Full Text] [Related]
9. Tumor Microenvironment Analysis Identified Subtypes Associated With the Prognosis and the Tumor Response to Immunotherapy in Bladder Cancer.
Zhang H; Song J; Dong J; Liu Z; Lin L; Wang B; Ma Q; Ma L
Front Genet; 2021; 12():551605. PubMed ID: 33732281
[No Abstract] [Full Text] [Related]
10. Identification of an Immune-Related Risk Signature Correlates With Immunophenotype and Predicts Anti-PD-L1 Efficacy of Urothelial Cancer.
Li P; Hao S; Ye Y; Wei J; Tang Y; Tan L; Liao Z; Zhang M; Li J; Gui C; Xiao J; Huang Y; Chen X; Cao J; Luo J; Chen W
Front Cell Dev Biol; 2021; 9():646982. PubMed ID: 33816497
[TBL] [Abstract][Full Text] [Related]
11. Association of Long Noncoding RNA Biomarkers With Clinical Immune Subtype and Prediction of Immunotherapy Response in Patients With Cancer.
Yu Y; Zhang W; Li A; Chen Y; Ou Q; He Z; Zhang Y; Liu R; Yao H; Song E
JAMA Netw Open; 2020 Apr; 3(4):e202149. PubMed ID: 32259264
[TBL] [Abstract][Full Text] [Related]
12. MHC-II Signature Correlates With Anti-Tumor Immunity and Predicts anti-PD-L1 Response of Bladder Cancer.
Yi R; Hong S; Zhang Y; Lin A; Ying H; Zou W; Wang Q; Wei T; Cheng Q; Zhu W; Luo P; Zhang J
Front Cell Dev Biol; 2022; 10():757137. PubMed ID: 35223828
[TBL] [Abstract][Full Text] [Related]
13. Tumour microenvironment-based molecular profiling reveals ideal candidates for high-grade serous ovarian cancer immunotherapy.
Lu X; Ji C; Jiang L; Zhu Y; Zhou Y; Meng J; Gao J; Lu T; Ye J; Yan F
Cell Prolif; 2021 Mar; 54(3):e12979. PubMed ID: 33522069
[TBL] [Abstract][Full Text] [Related]
14. Identification and Validation of a Stromal EMT Related LncRNA Signature as a Potential Marker to Predict Bladder Cancer Outcome.
Du Y; Wang B; Jiang X; Cao J; Yu J; Wang Y; Wang X; Liu H
Front Oncol; 2021; 11():620674. PubMed ID: 33747932
[TBL] [Abstract][Full Text] [Related]
15. Identification of an immune classification for cervical cancer and integrative analysis of multiomics data.
Lyu X; Li G; Qiao Q
J Transl Med; 2021 May; 19(1):200. PubMed ID: 33971902
[TBL] [Abstract][Full Text] [Related]
16. An RNA-sequencing-based transcriptome for a significantly prognostic novel driver signature identification in bladder urothelial carcinoma.
Liu D; Zhou B; Liu R
PeerJ; 2020; 8():e9422. PubMed ID: 32742772
[TBL] [Abstract][Full Text] [Related]
17. Multi-omics Perspective on the Tumor Microenvironment based on PD-L1 and CD8 T-Cell Infiltration in Urothelial Cancer.
Chen S; Zhang N; Shao J; Wang T; Wang X
J Cancer; 2019; 10(3):697-707. PubMed ID: 30719168
[No Abstract] [Full Text] [Related]
18. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
19. Application of PD-1 Blockade in Cancer Immunotherapy.
Wu X; Gu Z; Chen Y; Chen B; Chen W; Weng L; Liu X
Comput Struct Biotechnol J; 2019; 17():661-674. PubMed ID: 31205619
[TBL] [Abstract][Full Text] [Related]
20. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ
J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
